Burixafor

Drug Profile

Burixafor

Alternative Names: TG-0054; Wembley Suffolk - TaiGen Biotechnology

Latest Information Update: 01 Sep 2015

Price : $50

At a glance

  • Originator TaiGen Biotechnology
  • Class Anti-ischaemics; Eye disorder therapies; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stem cell mobilisation
  • No development reported Age-related macular degeneration; Diabetic retinopathy

Most Recent Events

  • 01 Sep 2015 Phase-II development is ongoing for Stem cell mobilisation in Taiwan
  • 18 Mar 2015 TaiGen plans phase II trials for stem cell mobilisation in Germany and China
  • 01 Apr 2014 TaiGen plans a phase II trial for Stem cell mobilisation (in combination with G-CSF in patients with haematological malignancies) in the USA (NCT02104427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top